off baseI think you guys have forgotten what was said on the call. I really don't think that there will be a buyout, that is not the model they were looking at. The partnership will be with a company who will sponsor, run, and manage the trials and, once completed will make an evaluation of strategic exit options. There will be an exit strategy but we are not there yet. We are looking for a group who specializes in companies where the drug didn't fail but the "trial failed the drug". We need a company who specializes in Phase II/III trials and data management.
This drug is worth more than .24!!!